← boardnext 2028-11-02
TSHA
Taysha Gene Therapies, Inc.distress 2/10 · well-funded / low risk$5.53-2%today-21% from 52w high
Lead: Rett syndrome
Revenue
pre-revenue
Liquidity
$277M
Runway
2.5 yrs
Shares 1y
+5%
Price & events
+8.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.4%
1D
-7.5%
1W
-19.5%
1M
-13.7%
3M
+18.6%
6M
+105.4%
1Y
+141.3%
2Y
-70.5%
5Y
-78.9%
All
Overview
- Market Cap
- $1.59B
- Enterprise Value
- $1.36B
- Volume
- 80.17K
- 52 Week Range
- $2.51 – $6.98
- Total Shares
- 287.36M
- Float Shares
- 205.97M
- Short %
- 14.67%
- % Held by Insiders
- 9.63%
- % Held by Institutions
- 86.19%
- RVOL
- 0.02x
- Beta
- 1.16
Pipeline stages · 1 programs
TSHA-102
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-11-02 Estimated 50% readout ~2028-12-17 | Phase 1/2 | TSHA-102rmatbreakthroughorphanfast trackrare pediatric | Rett Syndrome | — | active not recruiting |
| 2031-06 Estimated 50% readout ~2031-08-15 | Phase 3 | TSHA-102rmatbreakthroughorphanfast trackrare pediatric | Rett Syndrome | — | recruiting |
| 2031-06 Estimated 50% readout ~2031-08-15 | Phase 3 | TSHA-102rmatbreakthroughorphanfast trackrare pediatric | Rett Syndrome | — | recruiting |
Catalyst news & presentations · 7
- first half of 2027Guided 55%readoutPhase 3TSHA-102 · Topline interim analysis and FDA feedback on BLA submission pathwaySEC 8-K
- 2026-08-12earningsEarningsEarnings releaseyahoo
- July 2026Estimated 45%enrollment completesecondaryPhase 1/2TSHA-102 · Dosing of one additional patient in ASPIRE trialSEC 8-K
- Q4 2025trial initiationsecondaryTSHA-102 · Initiate patient enrollment in REVEAL pivotal trialSEC 8-K
- 2025-10-02fda agreementTSHA-102 · Finalized alignment with FDA on REVEAL pivotal trial protocol and statistical analysis planSEC 8-K
- Q3 2025trial initiationsecondaryPhase 3TSHA-102 · Initiate pivotal Part B trialSEC 8-K
- current quarterregulatory submissionFiled (NDA/BLA)TSHA-102 · Submit pivotal Part B trial protocol and SAP as IND amendmentSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $13 (+135% upside) · 13 analysts
- 2026-07-21Goldman SachsBuy
- 2026-07-02CitizensMarket Outperform
- 2026-06-30BairdOutperform
- 2026-06-30NeedhamBuy
- 2026-06-23BMO CapitalOutperform
- 2026-06-23B of A SecuritiesBuy
Competitors — Rett syndrome
- NGNENeurogene Inc.$566M · D3
Recent news
- 2026-07-21TSHA Maintains Buy Rating -- Price Target Raised to $13.00 by Go - GuruFocus
- 2026-07-21TSHA Maintains Buy Rating -- Price Target Raised to $13.00 by Go - GuruFocus
- 2026-07-15Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In - Yahoo Finance
- 2026-07-11Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha G - GuruFocus
- 2026-07-11Taysha Gene Therapies president sells $1.25m in stock By Investing.com - Investing.com Nigeria
- 2026-07-10Taysha Gene Therapies (NASDAQ: TSHA) R&D chief sells 200,000 shares under plan - Stock Titan
- 2026-07-10Taysha Gene Therapies (TSHA) investor files to sell 200,000 shares via Jefferies - Stock Titan
- 2026-07-08Will Russell Index Removals and New Rett Data Change Taysha Gene Therapies' (TSHA) Narrative? - simplywall.st
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.